Latest Safety News

Chimeric Therapeutics has appointed Hawkesbury Partners to lead a strategic review aimed at exploring options to enhance shareholder value, reflecting concerns that its market cap undervalues its clinical assets and infrastructure.

RocketDNA has fully deployed its Skylink® Operating System to all enterprise customers, driving over 1,000 active users and securing a 12-month pipeline of 25,000 pre-scheduled drone missions.

Imugene Limited reports a complete response in the first patient treated with azer-cel combined with BTK inhibitors in its Phase 1b trial, highlighting potential for resistant follicular lymphoma.

Latrobe Magnesium has reached a third of construction completion at its Phase 1B Demonstration Plant, maintaining strong safety standards and progressing key installation milestones. The company targets first magnesium metal output in the second half of 2026, aligning with prior guidance.

ikeGPS Group Limited reported a 33% surge in subscription revenue to NZ$19.2 million for FY26, driven by AI-powered product innovation and expanding adoption among North American utilities. The company achieved positive underlying EBITDA in March and ended the year with NZ$33 million cash and no debt.

Mainfreight Limited’s 2026 Annual Report reveals a 2.8% rise in revenue to NZ$5.38 billion, while profit before tax slipped 8.5% to NZ$351 million. The integrated logistics group is investing heavily in property and technology, advancing sustainability despite regional profit challenges.

Macarthur Minerals narrowed its loss to $1.82 million for FY26, bolstered by a major new investor and joint venture at its Lake Giles iron ore project in Western Australia.

Sprintex Limited has locked in underwriting agreements covering 8.7 million unexercised options, potentially raising up to A$870,000. The company also agreed to extend a A$1.85 million convertible note maturity by one year, pending shareholder approval.

HITIQ Limited has secured $1.4 million through a private placement of 200 million shares at 0.7 cents each, accompanied by options exercisable until 2029. The capital will bolster its balance sheet and back expansion and commercialisation efforts.

Clarity Pharmaceuticals will present compelling data at EANM 2026 demonstrating its 64Cu-SAR-bisPSMA imaging agent’s superior detection of prostate cancer recurrence and promising therapeutic results from 67Cu-SAR-bisPSMA in advanced disease.

Environmental Clean Technologies (ASX: ECT) has submitted detailed data to the US EPA showcasing its Rapid Electrothermal Mineralisation (REM) technology's ability to destroy PFAS with over 99% efficacy and full fluorine mass balance, aiming to meet stringent regulatory standards.

SRJ Technologies' subsidiary ACE inks a strategic MOU with Australian robotics leader Nexxis, aiming to combine cutting-edge robotic platforms with advanced data analytics to enhance asset inspections in the energy sector.